References
- Hagberg B, Hagberg G, Beckung E, Uvebrandt P. Changing panorama of cerebral palsy in Sweden. VIII. Prevalence and origin in the birth period 1991–94. Acta Paediatr 2001; 90: 271–7
- Wasiak J, Hoare B, Wallen M. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (Cochrane Review). In: Cochrane Library. Issue 3. Chichester: John Wiley; 2004.
- Boyd RN, Morris ME, Graham HK. Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol 2001; 8(suppl 5)150–66
- Wong V. Evidence-based approach to the use of botulinum toxin type A (BXT) in cerebral palsy. Pediatr Rehabil 2003; 6: 85–96
- Sackett D. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989; 95(suppl 2)2S–4S
- Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997; 39: 185–93
- Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000; 137: 331–7
- Friedman A, Diamond M, Johnston MV, Daffner C. Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. Am J Phys Med Rehabil 2000; 79: 53–9
- Autti-Rämö I, Larsen A, Taimo A, von Wendt L. Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications. Eur J Neurol 2001; 8(suppl 5)136–44
- Wong V, Ng A, Sit P. Open-label study of botulinum toxin for upper limb spasticity in cerebral palsy. J Child Neurol 2002; 17: 138–42
- Yang TF, Fu CP, Kao NT, Chan RC, Chen SJ. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil 2003; 82: 284–9
- Wallen MA, O'Flaherty SJ, Waught MC. Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rehabil 2004; 85: 192–200
- WHO. ICF, International Classification of Functioning, Disability and Health. Geneva: World Health Organization; 2001.
- Zancolli EA. Structural and dynamic bases of hand surgery2nd ed. Lippincott, Philadelphia 1979
- House JH, Gwathmey FW, Fidler MO. A dynamic approach to the thumb-in palm deformity in cerebral palsy. J Bone Joint Surg 1981; 63A: 216–25
- Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206–7
- Häger-Ross C, Rösblad B. Norms for grip strength in children aged 4–16 years. Acta Paediatr 2002; 91: 617–25
- Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP, Rodgers H. A review of the properties and limitations of the Ashworth and modified Ashworth scales as measures of spasticity. Clin Rehabil 1999; 13: 373–83
- Pandyan AD, Vuadens P, van Wijck FMJ, Stark S, Johnson GR, Barnes MP. Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength, and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population. Clin Rehabil 2002; 16: 654–60
- Jefferson RJ. Botulinum toxin in the management of cerebral palsy. Dev Med Child Rehabil 2004; 46: 491–9
- Koman LA, Smith BP, Shilt JS. Cerebral palsy. Lancet 2004; 363: 1619–31
- Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594–602